Frequently Asked Questions on the Strategic Value of Dual Branding in Pharma

Andrea: You’ll effectively have no option other than dual branding in a narrow set of situations. Health authorities will expect or sometimes require separate identities if a product is approved for two distinct indications with very different risk-benefit profiles. The clearest case is when a molecule serves clinically distinct indications with different doses, populations, and prescribing logic. Everolimus is a textbook example: Novartis markets the same molecule as Afinitor^® and Votubia^® in oncology, and as Certican^® and Zortress^® in transplant immunosuppression. The dosing differences alone make conflating the brands a safety problem, not a marketing inconvenience.

Dual branding is also likely required if a reformulation changes the clinical use case enough that conflating the two would create safety or prescribing confusion. The same applies to certain biosimilar and originator configurations, or to licensing arrangements where a co-marketing partner needs a distinct brand to operate in their territory.

Everything else is a strategic decision. The strategic cases of dual branding are where most of the value—and most of the mistakes—sit, in my experience. The most frequent mistake occurs when companies treat dual branding as something that happens late in the process, usually when a pricing problem surfaces in a specific market. By then, your options are narrower, and the justification is harder to build. The companies that get the most out of dual branding are the ones that ask the question early, during Phase II or III planning, when you can still design clinical differentiation rather than retrofit it later.

Andrea: Dual branding creates parallel revenue streams without forcing a single pricing logic across every market you operate in. One brand can anchor the premium private or specialty channel; the second can capture volume in public or tender-driven systems. That’s the headline mechanism.

In practice, the value tends to show up across three segments. The first is payer-differentiated: hospital formularies, national systems, and private insurers have genuinely different value expectations, and a single brand rarely satisfies all of them without compromise. The second is patient sub-populations: differences in disease severity, adherence profiles, or socioeconomic context mean the same molecule can justify different access pathways. The third is geographic: in markets with aggressive reference pricing, a distinct brand identity can protect premium positioning elsewhere while allowing competitive access locally.

The revenue story depends entirely on how clearly—and early—you define dual differentiation. Some companies frame dual branding as a flexibility tool for pricing. Flexibility without a pricing architecture is just inconsistency, however, and payers see through it quickly.

Andrea: Dual branding can strengthen credibility if the differentiation is visible, consistent, and defensible. Done well, the two brands don’t compete; they complement. One might carry the innovation narrative, the other the access commitment. That kind of architecture signals to external stakeholders that you understand their context.

One condition is that the dual branding strategy must genuinely reflect different value propositions, such as distinct clinical data packages, tailored health economic models, and fit-for-purpose access programs. Otherwise, dual branding starts to look like price manipulation, particularly when regulators or payers notice two brands with the same active ingredient priced very differently without a convincing clinical rationale.

In today’s pricing environment, ambiguity isn’t neutral. It’s a liability.

Andrea: This is where your strategy comes into play. A second brand, priced lower and supported by a tailored value dossier, can reach typically excluded patient populations without collapsing the pricing structure of the premium brand. This second brand addresses three specific barriers.

Affordability is the clearest one: a differentiated price point, grounded in a distinct health economic story, opens the door to patients who couldn’t access the premium brand. Formulary and reimbursement is the second: in markets with restrictive listing criteria, a second brand can be designed around what national payers actually need to see in order to list. And the third is channel and distribution: in fragmented or lower-infrastructure markets, a distinct brand can support different distribution models or slot into public procurement frameworks in ways the premium brand never could.

The point is that access and premium positioning don’t have to be in tension. Dual branding is one of the few tools that lets you hold both at once.

Andrea: The strongest markets for dual branding tend to be middle-income countries with dual public-private health systems, e.g., Brazil, Mexico, Turkey, Poland, Egypt, parts of Southeast Asia. A single brand genuinely struggles to serve both the private premium channel and the national health system in these markets, and dual branding resolves a tension that would otherwise force a compromise. You may also find emerging markets in sub-Saharan Africa and South Asia relevant, particularly where global health partnerships or tiered pricing are already part of the access strategy.

On the therapeutic side, the highest-impact areas are those where patient stratification is clinically meaningful. Oncology and rare diseases are obvious examples. However, chronic conditions, like diabetes and cardiovascular, also qualify, because you can anchor differentiated access programs in real clinical segmentation rather than marketing narrative.

Andrea: This is probably the most urgent application of dual branding today. MFN clauses create structural constraints on how you price across markets and segments. Dual branding is one of the few defensible tools companies have to navigate that exposure.

The mechanism is straightforward in principle. Companies can treat two brands as separate reference products for MFN and IRP purposes when they are supported by genuinely differentiated clinical packages, e.g., different indications, formulations, or patient populations. A lower price granted under Brand B doesn’t automatically trigger a price reduction obligation for Brand A elsewhere, provided the differentiation is credible and holds up to regulatory scrutiny.

The risk, though, is equally real. Health authorities and regulators are scrutinizing dual branding arrangements much more closely through an MFN lens, and the bar is rising. If two brands are deemed functionally identical, but are marketed under different names primarily to work around reference pricing, the consequences include forced price alignment, retroactive clawbacks, formulary exclusion, and reputational damage that outlasts the specific product. The implication is that companies must architect the differentiation from the outset, document it carefully, and build it to withstand payer and regulatory challenges. Dual branding as an MFN workaround doesn’t survive contact with today’s regulators. Dual branding as a genuinely differentiated commercial strategy does.

Andrea: Four things tend to separate the dual branding strategies that work from the ones that unravel,

The first is designing the brand architecture so it withstands payer, HTA, and regulatory scrutiny from day one, not retrofitting justification after a market problem surfaces. The second is defining defensible clinical, economic, and pricing differentiation between the brands, grounded in evidence rather than positioning. The third is assessing IRP and MFN exposure early and structuring the pricing architecture around it. The fourth, and often the hardest in practice, is aligning global, regional, and local stakeholders so the strategy is executed consistently across affiliates.